Welcome to the e-CCO Library!

P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Angriman, G. Bordignon, E. Sciuto, O. Zini, N. Bortoli, M. Gruppo, R. Bardini, C. Ruffolo, M. Scarpa

Created: Thursday, 30 January 2020, 10:12 AM
P533: Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Year: 2021
Source: ECCO'21 Virtual
Authors: Calvo Moya, M.I.(1);Omella Usieto, I.(2);El Hajra Martinez, I.(2);Santos Perez, E.(2);Gonzalez Lama, Y.(1);Ruiz Antoran, B.(3);Menchen Viso, B.(4);Matallana Royo, V.(1);Gonzalez Partida, I.(1);De Lucas Tellez de Meneses, R.(1);Bella del Castillo, P.(1);Gonzalez Rodriguez, M.(1);Vera Mendoza, M.I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P533: Anaemia and iron deficiency in gastroenterology: a Scandinavian prospective, observational study of iron isomaltoside in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Frigstad S.O.*1,2,3, Hammarlund P.4, Bonderup O.5, Rannem T.6, Haaber A.7, Fallingborg J.8, Blom H.9, Bajor A.10,11, Hellström P.M.12

Created: Wednesday, 20 February 2019, 10:36 AM
P533: Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study
Year: 2018
Source: ECCO '18 Vienna
Authors:

W.J. Sandborn1*, B. Feagan2, J.D. Lewis3, S. Danese4, W. Reinisch5, D.T. Rubin6, W. Zhou7, F. Cataldi7, Q. Zhou7, S. Goteti7, A.P. Lacerda7

Created: Thursday, 21 February 2019, 9:14 AM
P533: Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
Year: 2022
Source: ECCO'22
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Sabino, J.(2,3);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P533: Relation between TL1A expression in intestinal mucosa, and endoscopic severity and clinical course in ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Shimodaira, Y.(1)*;Yoshida, T.(1);Watanabe, K.(1);Takahashi, S.(1);Fukuda, S.(1);Koizumi, S.(1);Matsuhashi, T.(1);Iijima, K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P533: Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Heron*1,2, T. Bessissow1, A. Bitton1, P. Lakatos1, E. Seidman1, A. Jain3, R. Battat1,4, P. Germain1, C. Lemieux1, W. Afif1

Created: Friday, 22 February 2019, 9:41 AM
P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Popov1,2, E. Hartung1, L. Hill1,3, U. Chauhan4, N. Pai1,5, McMaster Paediatric FMT Research Program

Created: Thursday, 30 January 2020, 10:12 AM
P534: Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cohen, S.(1);Olbjorn, C.(2);Kolho, K.L.(3); Aloi, M.(4);Musto, F.(4);de-Carpi, J.M.(5);Lozano-Ruf, A.(5);Yogev, D.(6);Matar, M.(7);Scarallo, L.(8); Bramuzzo, M.(9); de Ridder, L.(10); Kang, B.(11);Norden, C.(12);Wilson, D.C.(13);Tzivinikos, C.(14); Turner, D.(6);Yerushalmy-Feler, A.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P534: Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission
Year: 2022
Source: ECCO'22
Authors: Gros , B.(1);Soto Escribano , P.(1);Marín Pedrosa , S.(1);Medina Medina , R.(2);Benítez , J.M.(1);Iglesias-Flores , E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P534: IBD-related malignancies observed in 2015–2018: 4 years’ results from the prospective nationwide Hungarian registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Milassin*1, M. Rutka1, K. Farkas1, A. Bálint1, R. Bor1, A. Fábián1, Z. Szepes1, T. Szamosi2, K. Szántó1, P. Miheller3, Z. Barta4, J. Banai2, Á. Kovács5, Á. Salamon6, L. Lakatos7, L. Lakner7, K. Palatka8, M. Papp9, E. Schafer2, J. Novák10, Z. Erdélyi11, Z. Kürti12, P. L. Lakatos12, P. Sarlós13, N. Szigeti14, G. Veres9, A. Zaránd16, A. Gelley17, Á. Vincze18, F. Nagy1, T. Molnár1

Created: Friday, 22 February 2019, 9:41 AM
P534: Illness perception in IBD patients: a prospective study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vegni E.1, Gilardi D.2, Corrò B.E.3, Menichetti J.4, Bonovas S.5, Leone D.1, Allocca M.2, Furfaro F.2, Danese S.2,6, Fiorino G.*7

Created: Wednesday, 20 February 2019, 10:36 AM
P534: Spontaneous intra-abdominal abscess in Crohn's disease: Efficacy of non-surgical management and prognostic factors
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Labidi1*, S. Hamdi1, M. Ben Abbes1, N. Ben Mustapha1, M. Hafi1, H. Maghrebi2, M. Fekih1, L. Zouiten1, M. Serghini1, J. Boubaker1

Created: Thursday, 21 February 2019, 9:14 AM
P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

X. Roblin1, A. Serone2, O.K. Yoon3, L. Zhuo3, E. Grant4, J. Woo5, J. Liu3, R. Galien6, G. D’Haens7

Created: Thursday, 30 January 2020, 10:12 AM
P535: Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre study
Year: 2022
Source: ECCO'22
Authors: Aleman Gonzalez, H.(1);Sankaranarayanan, R.(1);Pattinson, A.(1);Turnbull, J.(1);Katie, S.(1);Whitehead, E.(1);Talbot, A.(1);Myers, S.(1);Sebastian, S.(1);
Created: Friday, 11 February 2022, 3:56 PM
P535: Azathioprine vs. mesalamine for prevention of post-operative clinical relapse in Crohn’s disease patients with severe endoscopic recurrence: data on efficacy and safety from an IG-IBD multi-centre randomised double-blind double-dummy trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Orlando*1, F. Mocciaro2, M. Ventimiglia1, S. Renna1, D. Scimeca2, A. Rispo3, M. L. Scribano4, A. Testa3, A. Aratari5, F. Bossa6, E. Angelucci7, S. Onali8, M. Cappello9, M. Giunta10, F. Castiglione3, C. Papi5, V. Annese6, L. Biancone8, A. Kohn4, R. Di Mitri2, M. Cottone11

Created: Friday, 22 February 2019, 9:41 AM
P535: COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, Z.(1)*;Alexander, J.(1);Le, K.(1);Zhou, X.(1);Ibraheim, H.(1);Anandabaskaran, S.(1);Saifuddin, A.(1);Lin, K.(2);Mcfarlane, L.(2);Anand, N.(1);Constable, L.(1);Castro-Seoane, R.(1);Nice, R.(3);Bewshea, C.(3);D'Mello, A.(4);Jones, G.R.(5);Balarajah, S.(1);Fiorentino, F.(6);Sebastian, S.(7);Irving, P.(8);Hicks, L.(1);Williams, H.(1);Kent, A.(9);Linger, R.(10);Parkes, M.(11);Kok, K.(12);Patel, K.V.(13);Teare, J.(14);Altmann, D.(15);Hart, A.(16);Lees, C.(5);Boyton, R.(15);Goodhand, J.(3);Kennedy, N.(3);Pollock, K.(2);Ahmad, T.(3);Powell, N.(1);
Created: Friday, 14 July 2023, 11:05 AM
P535: Optimising vedolizumab in treatment sequences for Crohn’s disease: Results from a simulation model using real-world evidence
Year: 2021
Source: ECCO'21 Virtual
Authors: Louis, E.(1);Nikolaou, A.(2);Litkiewicz, M.(2);Agboton, C.(3);Wang, S.(4);Armuzzi, A.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P535: Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gulati S., Emmanuel A., Burt M., Hayee B., Haji A.

Created: Wednesday, 20 February 2019, 10:36 AM